### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   MIZELL STEVEN

2. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)
   10/28/2022

4. If Amendment, Date Original Filed (MM/DD/YYYY)

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
   _X_ Director
   ___ 10% Owner
   ___ Officer (give title below)  _X_ Other (specify below)
   EVP, Chief HR Officer

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Amount</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>M</td>
<td>17000</td>
<td>$0</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>S</td>
<td>17000</td>
<td>$100.00</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>S</td>
<td>8000</td>
<td>$98.84</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Amount</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$70.71 (1) 10/28/2022</td>
<td>M</td>
<td>17000</td>
<td>10/30/2019</td>
<td>10/29/2028</td>
</tr>
<tr>
<td>Common Stock</td>
<td></td>
<td></td>
<td>17000</td>
<td>$0</td>
<td>35824</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.8400 to $98.8450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

2. Holdings include shares acquired in dividend reinvestment transactions.

3. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

4. The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIZELL STEVEN</td>
<td>Director 10% Owner Officer Other</td>
</tr>
<tr>
<td>MERCK &amp; CO. 126 EAST LINCOLN AVENUE RAHWAY, NJ 07065</td>
<td>EVP, Chief HR Officer</td>
</tr>
</tbody>
</table>

Signatures

/s/ Kelly E. W. Grez as Attorney-in-Fact for Steven C. Mizell 11/1/2022
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.